The use of single sample clearance estimates to probe hepatic drug metabolism: Handprinting the influence of phenobarbitone on human hepatic drug metabolism

References

• Bachmann K., Nunlee M., Martin M., Schwartz J., Jauregue L., Forney J. R. The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of cigarette smoking on human hepatic drug metabolism. Xenobiotica 1990; 20: 537–547
   PubMed Web of Science ®Google Scholar
• Baille T., Rettenmeir A. Valproate: biotransformation. Antiepileptic Drugs, R. H. Levy, F. Dreifuss, R. Maitson, B. Meldrum, J. K. Penry. Raven Press, New York 1989; 601–619
   Google Scholar
• Browne T., Szabo G., Evans J., Evans B., Greenblatt D., Mikati M. Phenobarbital does not alter phenytoin steady-state serum concentration of pharmacokinetics. Neurology 1988; 38: 639–642
   PubMed Web of Science ®Google Scholar
• Campbell N., Grant D., Inaba T., Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metabolism and Disposition 1987; 15: 237–249
   PubMed Web of Science ®Google Scholar
• Dossing M., Pilsgaard H., Rasmussen B., Poulsen H. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. European Journal of Clinical Pharmacology 1983; 25: 215–222
   PubMed Web of Science ®Google Scholar
• Dreifuss F., Santilli N., Langer D., Sweeney K., Moline K., Menander K. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379–385
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Tomson T., Tybring G., Bertilsson L. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clinical Pharmacokinetics 1985; 10: 80–90
   PubMed Web of Science ®Google Scholar
• Goldstein E., Eney R., Mellits E., Solomon H., Johnson G. The effect of phenobarbital on theophylline metabolism in asthmatic children. Annals of Allergy 1977; 39: 19
   Google Scholar
• Greene J., Danish M., Ragni M., Lecks H., Yaffe S. The effect of phenobarbital upon theophylline elimination kinetics in asthmatic children. Annals of Allergy 1977; 39: 69
   Google Scholar
• Guengerich F. P., Muller-Enoch D., Blair I. Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology 1986; 30: 287–295
   PubMed Web of Science ®Google Scholar
• Heller F., Desager J., Harvengt C. Changes in plasma activities of lipolytic enzymes and lipids of normolipodemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1983; 26: 138–142
   Google Scholar
• Hepner G., Vesell E. S. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of [14C]-aminopyrine. New England Journal of Medicine 1974; 291: 1384–1388
   PubMed Web of Science ®Google Scholar
• Jusko W., Gardner M., Mangione A., Schentag J., Koup J., Vance J. Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, barbiturates, and ethanol. Journal of Pharmaceutical Science 1979; 68: 1358–1366
   PubMed Web of Science ®Google Scholar
• Kalow W. Genetic variation in the human hepatic cytochrome P-450 system. European Journal of Clinical Pharmacology 1987; 31: 633–641
   PubMed Web of Science ®Google Scholar
• Landay R., Gonzalez M., Taylor J. Effect of phenobarbital on theophylline disposition. Journal of Allergy and Clinical Immunology 1978; 62: 27–29
   PubMed Web of Science ®Google Scholar
• Leclercq V., Desager J., Horsmans Y., Van Nieuwenhuyze Y., Harvengt C. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1989; 12: 593–598
   Google Scholar
• Loft S. Metronidazloe and antipyrine as probes for the study of foreign compound metabolism. Pharmacology and Toxicology 1990; 66(Suppl VI)1–31
   PubMedGoogle Scholar
• May T., Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication. Therapeutic Drug Monitoring 1985; 7: 387–390
   PubMed Web of Science ®Google Scholar
• Okey A. Enzyme induction in the cytochrome P-450 system. Pharmacology and Therapy 1990; 45: 241–198
   PubMed Web of Science ®Google Scholar
• Ohnhaus E., Kirchhof B., Peheim E. Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin. Clinical Phamacology and Therapeutics 1979; 25: 591–597
   PubMed Web of Science ®Google Scholar
• Pantuck E., Kuntzman R., Conney. Decreased concentration of phenacetin in plasma of cigarette smokers. Science 1972; 175: 1248–1250
   PubMed Web of Science ®Google Scholar
• Park B., Wilson A., Kaatz G., Ohnhous E. Enzyme induction by phenobarbitone and vitamin K1 disposition in man. British Journal of Clinical Pharmacology 1984; 18: 94–97
   PubMed Web of Science ®Google Scholar
• Park B. K., Breckenridge A. M. Clinical implications of enzyme induction and enzyme inhibition. Clinical Pharmacokinetics 1981; 6: 1–24
   PubMed Web of Science ®Google Scholar
• Piafsky K., Sitar D., Ogilvie R. Effect of phenobarbital on the disposition of intravenous theophylline. Clinical Pharmacology and Therapeutics 1977; 22: 336–339
   PubMed Web of Science ®Google Scholar
• Price D., Mehta A., Park B. K., Hay A., Feely M. The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction. British Journal of Clinical Pharmacology 1986; 22: 744–747
   PubMedGoogle Scholar
• Roberts C., Jackson L., Halliwell M., Branch R. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration. British Journal of Clinical Pharmacology 1976; 3: 907–913
   PubMed Web of Science ®Google Scholar
• Rose J., Barron S., Jusko W. Phenytoin disposition in smokers and non-smokers. International Journal of Clinical Pharmacology 1978; 16: 547–550
   Google Scholar
• Rutledge D., Pieper J., Mirvis D. Effects of chronic phenobarbital on verapamil disposition in humans. Journal of Pharmacology and Experimental Therapeutics 1988; 246: 7–13
   PubMed Web of Science ®Google Scholar
• Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clinical Pharmacology and Therapeutics 1979; 26: 275–286
   PubMed Web of Science ®Google Scholar
• Watkins P., Hamilton T., Annesley T., Ellis C., Kolars J., Voorhees J. The erythrcmycin breath test as a predictor of cyciosporine blood levels. Clinical Pharmacology and Therapeutics 1990; 48: 120–129
   PubMed Web of Science ®Google Scholar